

Advanced Vaccine Research

Methods for the Decade of Vaccines

Edited by

Fabio Bagnoli and Rino Rappuoli

Novartis Vaccines
Research Center
Siena
Italy



Copyright © 2015

Caister Academic Press
Norfolk, UK

www.caister.com

British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library

ISBN: 978-1-910190-03-6 (hardback)

ISBN: 978-1-910190-04-3 (ebook)

Description or mention of instrumentation, software, or other products in this book does not imply endorsement by the author or publisher. The author and publisher do not assume responsibility for the validity of any products or procedures mentioned or described in this book or for the consequences of their use.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher. No claim to original U.S. Government works.

Cover design adapted from Figures 3.1 and 3.2

Contents

	Contributors	v
	Preface	xi
Part I	Innovative Technologies and Approaches in Vaccine Research	1
1	Deep Sequencing in Vaccine Research, Development and Surveillance Stefano Censini, Silvia Guidotti, Giulia Torricelli, Rino Rappuoli and Fabio Bagnoli	3
2	New Bioinformatics Algorithms Applied to Deep Sequencing Projects Mina Rho	33
3	Comparative Genomics Approaches for Tracking the Emergence and Spread of Disease-associated Bacteria Tracy H. Hazen and David A. Rasko	65
4	Quantitative Proteomics in Vaccine Research Massimiliano Biagini and Nathalie Norais	75
5	Structural Biology in Vaccine Research Danilo Donnarumma, Matthew J. Bottomley, Enrico Malito, Ethan Settembre, Ilaria Ferlenghi and Roberta Cozzi	103
6	Cellular Screens to Interrogate the Human T- and B-cell Repertoires and Design Better Vaccines Jens Wrammert and Kaja Murali-Krishna	133
7	Novel Strategies of Vaccine Administration: The Science Behind Epidermal and Dermal Immunization Béhazine Combadière and Hélène Perrin	157
8	Toll-like Receptors as Targets to Develop Novel Adjuvants Şefik Şanal Alkan	187
9	The Importance of Cell-mediated Immunity for Bacterial Vaccines Alison G. Murphy and Rachel M. McLoughlin	219
10	T-cell-inducing Vaccines Sarah Gilbert	251

11	Exploiting the Mutanome for Personalized Cancer Immunotherapy Ugur Sahin, Sebastian Kreiter, John C. Castle, Martin Löwer, Cedrik M. Britten and Özlem Türeci	263
Part II	Challenges for the Decade of Vaccines	271
12	Malaria Vaccine Development: Progress to Date Philip Bejon, Ally Olotu and Kevin Marsh	273
13	Tuberculosis Else Marie Agger and Peter Andersen	305
14	HIV-1 Vaccine Development Barton F. Haynes, Georgja D. Tomaras, Hua-Xin Liao and Andrew J. McMichael	335
15	Cancer Immunotherapy: The Road to Rejection Peter E. Fecci, Christina Chen, Susanne Baumeister and Glenn Dranoff	359
16	Global Health Vaccines Against the Invasive Salmonellosis: Enteric Fever and Invasive Non-typhoidal <i>Salmonella</i> Disease Calman A. MacLennan	387
17	The Path to a Respiratory Syncytial Virus Vaccine Christine A. Shaw, Max Ciarlet, Brian W. Cooper, Lamberto Dionigi, Paula Keith, Karen B. O'Brien, Maryam Rafie-Kolpin and Philip R. Dormitzer	411
18	<i>Staphylococcus aureus</i> Linhui Wang and Jean C. Lee	425
	Index	449
	Colour Plate	A1

Preface

Only clean water has contributed to improving global health more than vaccines (Andre *et al.*, 2008). Vaccines have completely, or nearly, eradicated some of the most deadly viral and bacterial infections (e.g. smallpox, poliomyelitis, diphtheria, tetanus, pertussis, measles, mumps and rubella) (Rappuoli *et al.*, 2011). On top of direct effects, by preventing infections in vaccinated subjects, vaccines also have a number of indirect benefits for the individual and society (Andre *et al.*, 2008). Indeed, vaccines can generate herd immunity, which plays a key role in protecting individuals at higher risk of infection including the immunocompromised, elderly and cancer patients, those in which the use of the vaccines is contraindicated, and those with limited or no access to resources to buy them. Vaccination has also been shown to reduce the incidence of certain cancers (Chang, 2003; Harper *et al.*, 2006). Indeed, some infective agents are associated with cancer, such as HBV with liver cancer and HPV with cervical cancer. Furthermore, vaccines are a key component in the fight against antibiotic resistance both directly and indirectly. By targeting bacterial pathogens, vaccines directly reduce the need for the use of antibiotics. Antiviral vaccines, such as the ones against influenza, can also have an indirect effect on reducing the emergence of antibiotic resistant strains by decreasing complications associated with super-infections, which routinely require antibiotic use.

Most of the vaccines currently available for human use were developed on the basis of Louis Pasteur's principle of inactivating or killing the infectious agent and then using it to induce protective immunity into the host (Rappuoli *et*

al., 2011). However, scientists have recently realized that for several pathogens (e.g. serogroup B *Neisseria meningitidis* (MenB), HIV, malaria), conventional vaccinology methods are not sufficient or adequate.

After the publication of the first bacterial genome in 1995 (Fleishmann *et al.*, 1995), it became clear that availability of the genomic sequence of pathogens was an invaluable source of information for vaccine research. In fact, only five years later, a new antigen identification approach, named reverse vaccinology, was applied to MenB (Pizza *et al.*, 2000). The approach was termed reverse vaccinology because antigens were selected prior to experimental testing (Rappuoli, 2000). Later, with the explosion of the omics era, vaccine discovery could benefit from techniques that generate data complementary to reverse vaccinology. With the advent of high-throughput sequencing technologies, the availability of multiple genomes of the same species allowed comparative genomics studies to be performed, critical to determine the level of conservation of vaccine candidates (He *et al.*, 2010).

However, none of the genomic approaches can provide all the information required for vaccine design and characterization. Techniques based on immunomics, such as the so-called antigenomics, can identify candidates expected to be immunogenic in humans (Meinke *et al.*, 2005; Rinaudo *et al.*, 2009; Vytvytska *et al.*, 2002). Approaches based on transcriptomics or proteomics are able to identify candidates expressed by pathogens under different growth conditions. Studies done to date using the different approaches have generally shown a significant degree of overlap and have

identified subsets of the surface and secreted antigens predicted by reverse vaccinology (Bagnoli *et al.*, 2011; Bensi *et al.*, 2012; Doro *et al.*, 2009; Etz *et al.*, 2002; Grifantini *et al.*, 2002; Rodriguez-Ortega *et al.*, 2006; Stranger-Jones *et al.*, 2006). However, each approach supplies different information that altogether can be used to select the best candidates.

Despite the recent progress made by omics science and high-throughput technologies we should not assume that vaccine research can be performed without the tight support of basic research. Indeed, it is still highly dependent on experimental studies and empirical observations. It is of critical importance to determine the role played by antigens in virulence, and interactions with the host, as well as their function and biochemical properties such as the structure. Structural biology represents a powerful means to identify protective epitopes, especially in highly variable antigens. Available vaccines are against pathogens whose antigens are relatively stable. Microbes that have rapid and extensive antigenic variability, remain a major challenge for vaccine researchers (Rappuoli and Aderem, 2011). Structural studies on the antigens can be performed to understand the degree of surface exposure of the epitopes and to design peptides optimized to generate neutralizing antibodies (Dormitzer *et al.*, 2008).

Another important aspect that requires a basic research approach is the discovery of mechanisms of protection. Pathogens against which successful vaccines have been developed, have known protective mechanisms and in all cases humoral response appears to be the driving mechanism (Moriel *et al.*, 2010). On the contrary, when protective mechanisms and correlate of protection are not clear (e.g. *Staphylococcus aureus*, malaria, HIV, *Candida albicans*, tuberculosis), successful vaccines could not be developed (Bagnoli *et al.*, 2012; Dubensky *et al.*, 2012; He *et al.*, 2010). Therefore, basic immunology studies to shed light on their mechanisms of protection are needed to support vaccine development against these pathogens. Accumulating literature indicate that innate and cell mediated immunity are important against several pathogens, such as *Mycobacterium*

tuberculosis (Doherty and Andersen, 2005; Hoft, 2008), *Candida albicans* and *S. aureus*.

In this regard, adjuvant formulations stimulating T-cell-mediated immunity are certainly another important area of investigation for next generation vaccines. Traditionally, adjuvants have been used to increase antibody-mediated responses. However, the important role of adjuvants in stimulating T-cell responses is also becoming clear. Recently, the role of Toll-like receptors as adjuvant targets is emerging as a promising area of investigation.

Usually, prior to clinical trials, most of the information available on protective efficacy of candidate vaccines is obtained in animal models and in *in vitro* studies. However, this approach has several limitations in predicting human immune response to vaccines. This is particularly true for those pathogens mentioned earlier for which correlate of protection in humans are unknown. Indeed, several failures in phase III clinical trials on HIV, malaria, and *S. aureus* have been recorded (Proctor, 2012; Shinefield *et al.*, 2002; Spellberg and Daum, 2010, 2012). The possibility to use different high-throughput technologies (e.g. next generation sequencing) to monitor the host response to vaccination and disease as well as to interrogate T- and B-cell repertoires in a large collection of individuals will allow the discovery of signatures of protection in humans. By integrating as many biological measurements as possible, systems biology will provide a powerful tool to analyse and interpret host responses to vaccines in clinical trials.

The aim of this book is therefore to illustrate the impressive technological advance that is increasing the quality standards of vaccines and is paving the way to develop vaccines against diseases for which efficacious medical treatments are still lacking. The examples that we have used comprise very different diseases; we include not only infectious diseases, but also cancer. We believe that these will be the vaccines of the future, the 'vaccines for 2020'.

References

Andre, F.E., Booy, R., Bock, H.L., Clemens, J., Datta, S.K., John, T.J., Lee, B.W., Lolekha, S., Peltola, H., Ruff, T.A., *et al.* (2008). Vaccination greatly reduces disease,

- disability, death and inequity worldwide. *Bull. World Health Organ.* 86, 140–146.
- Bagnoli, F., Baudner, B., Mishra, R.P., Bartolini, E., Fiaschi, L., Mariotti, P., Nardi-Dei, V., Boucher, P., and Rappuoli, R. (2011). Designing the next generation of vaccines for global public health. *OMICS* 15, 545–566.
- Bagnoli, F., Bertholet, S., and Grandi, G. (2012). Inferring reasons for the failure of *Staphylococcus aureus* vaccines in clinical trials. *Front. Cell. Infect. Microbiol.* 2, 16.
- Bensi, G., Mora, M., Tuscano, G., Biagini, M., Chiarot, E., Bombaci, M., Capo, S., Falugi, F., Manetti, A.G., Donato, P., *et al.* (2012). Multi high-throughput approach for highly selective identification of vaccine candidates: the group A streptococcus case. *Mol. Cell. Proteomics* 11, M111.015693.
- Chang, M.H. (2003). Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. *Liver Int.* 23, 309–314.
- Doherty, T.M., and Andersen, P. (2005). Vaccines for tuberculosis: novel concepts and recent progress. *Clin. Microbiol. Rev.* 18, 687–702.
- Dormitzer, P.R., Ulmer, J.B., and Rappuoli, R. (2008). Structure-based antigen design: a strategy for next generation vaccines. *Trends Biotechnol.* 26, 659–667.
- Doro, F., Liberatori, S., Rodriguez-Ortega, M.J., Rinaudo, C.D., Rosini, R., Mora, M., Scarselli, M., Altindis, E., D'Aurizio, R., Stella, M., *et al.* (2009). Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1. *Mol. Cell. Proteomics* 8, 1728–1737.
- Dubensky, T.W. Jr., Skoble, J., Lauer, P., and Brockstedt, D.G. (2012). Killed but metabolically active vaccines. *Curr. Opin. Biotechnol.* 23, 917–923.
- Etz, H., Minh, D.B., Henics, T., Dryla, A., Winkler, B., Triska, C., Boyd, A.P., Sollner, J., Schmidt, W., von Ahsen, U., *et al.* (2002). Identification of *in vivo* expressed vaccine candidate antigens from *Staphylococcus aureus*. *Proc. Natl. Acad. Sci. U.S.A.* 99, 6573–6578.
- Fleishmann, J.A., Mor, V., and Laliberte, L.L. (1995). Longitudinal patterns of medical service use and costs among people with AIDS. *Health Serv. Res.* 30, 403–424.
- Grifantini, R., Bartolini, E., Muzzi, A., Draghi, M., Frigimelica, E., Berger, J., Ratti, G., Petracca, R., Galli, G., Agnusdei, M., *et al.* (2002). Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. *Nat. Biotechnol.* 20, 914–921.
- Harper, D.M., Franco, E.L., Wheeler, C.M., Moscicki, A.B., Romanowski, B., Roteli-Martins, C.M., Jenkins, D., Schuind, A., Costa Clemens, S.A., and Dubin, G. (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *Lancet* 367, 1247–1255.
- He, Y., Rappuoli, R., De Groot, A.S., and Chen, R.T. (2010). Emerging vaccine informatics. *J. Biomed. Biotechnol.* 2010, 218590.
- Hoft, D.F. (2008). Tuberculosis vaccine development: goals, immunological design, and evaluation. *Lancet* 372, 164–175.
- Meinke, A., Henics, T., Hanner, M., Minh, D.B., and Nagy, E. (2005). Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens. *Vaccine* 23, 2035–2041.
- Moriel, D.G., Bertoldi, I., Spagnuolo, A., Marchi, S., Rosini, R., Nesta, B., Pastorello, I., Corea, V.A., Torricelli, G., Cartocci, E., *et al.* (2010). Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic *Escherichia coli*. *Proc. Natl. Acad. Sci. U.S.A.* 107, 9072–9077.
- Pizza, M., Scarlato, V., Masignani, V., Giuliani, M.M., Arico, B., Comanducci, M., Jennings, G.T., Baldi, L., Bartolini, E., Capecci, B., *et al.* (2000). Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. *Science* 287, 1816–1820.
- Proctor, R.A. (2012). Is there a future for a *Staphylococcus aureus* vaccine? *Vaccine* 30, 2921–2927.
- Rappuoli, R. (2000). Reverse vaccinology. *Curr. Opin. Microbiol.* 3, 445–450.
- Rappuoli, R., and Aderem, A. (2011). A 2020 vision for vaccines against HIV, tuberculosis and malaria. *Nature* 473, 463–469.
- Rappuoli, R., Mandl, C.W., Black, S., and De Gregorio, E. (2011). Vaccines for the twenty-first century society. *Nat. Rev. Immunol.* 11, 865–872.
- Rinaudo, C.D., Telford, J.L., Rappuoli, R., and Seib, K.L. (2009). Vaccinology in the genome era. *J. Clin. Invest.* 119, 2515–2525.
- Rodriguez-Ortega, M.J., Norais, N., Bensi, G., Liberatori, S., Capo, S., Mora, M., Scarselli, M., Doro, F., Ferrari, G., Garaguso, I., *et al.* (2006). Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. *Nat. Biotechnol.* 24, 191–197.
- Shinefield, H., Black, S., Fattom, A., Horwith, G., Rasgon, S., Ordonez, J., Yeoh, H., Law, D., Robbins, J.B., Schneerson, R., *et al.* (2002). Use of a *Staphylococcus aureus* conjugate vaccine in patients receiving hemodialysis. *New Engl. J. Med.* 346, 491–496.
- Spellberg, B., and Daum, R. (2010). A new view on development of a *Staphylococcus aureus* vaccine: insights from mice and men. *Human Vaccin.* 6, 857–859.
- Spellberg, B., and Daum, R. (2012). Development of a vaccine against *Staphylococcus aureus*. *Semin. Immunopathol.* 34, 335–348.
- Stranger-Jones, Y.K., Bae, T., and Schneewind, O. (2006). Vaccine assembly from surface proteins of *Staphylococcus aureus*. *Proc. Natl. Acad. Sci. U.S.A.* 103, 16942–16947.
- Vytvytska, O., Nagy, E., Bluggel, M., Meyer, H.E., Kurzbauer, R., Huber, L.A., and Klade, C.S. (2002). Identification of vaccine candidate antigens of *Staphylococcus aureus* by serological proteome analysis. *Proteomics* 2, 580–590.

- 1000 Genomes Project 34
16S rRNA 53, 65
- A**
- Acetic acid hydrolysis 399
Acinetobacter baumannii 72
Activation-induced cytidine deaminase (AID) 338
Acute lower respiratory infection 411
Adaptive immunity 219, 220
ADCC 348
Adenovirus 251, 256
AdH5 291
Adjuvants 134, 191, 317, 321, 324, 402, 420
Adoptive T-cell therapy 374–377
 chimeric antigen receptor (CAR) 374–377
Adults 388–390, 392, 399
Africa 387–392, 394, 398–399, 400
 Kenya 388
 Malawi 394
AIDS vaccine 335
Alignment 36
 $\alpha\beta$ T-cells 223, 224, 239
Alpha toxin 432–434
AltaStaph 430, 439
Aluminum salts 191
ALVAC-HIV/AIDSVAX gp120 B/E vaccine 348
Alveolitis 414
AMA-1 293, 279
Animal models 280
Antibiotic resistance 69, 70
Antibiotics 388, 391
Antibodies 220, 222, 239, 391–394, 396, 398–401
 affinity maturation 398
 class switching 395, 398
 IgA 393, 394
 IgG 392–394, 396
 IgG2a 394
 IgM 393
 monoclonal antibodies 392, 394
 mucosal antibodies 393, 398
Antigen–antibody complex 103–119, 122, 124–126
Antigen baiting 142
Antigen binding region 43
Antigen design 103, 105, 113–114, 116, 120, 122, 125–126
Antigen-presenting cells (APC) 157, 161, 163–164, 166–168, 171–173, 220, 223, 229
Antigens (*Salmonella*) 387, 388, 392–396, 398–403
 flagellin 388, 392, 394, 399, 400, 402
 O:2 393, 399
 O:4,5 393, 399
 O:9 393, 399, 400
 O-antigen 388, 392, 394, 395, 399, 401, 402
 OmpC 393, 394, 401
 OmpD 393, 394, 401
 OmpF 393, 394, 401
 SseB 394
 Vi 387, 388, 390, 392, 393, 396, 399, 400
Animal model 413
Anti-retroviral therapy (ART) 335
Apical merozoite antigen 1 293
 see also AMA-1
AS01 291
AS02 290
AS04 290
Asia 388–389, 398
 China 388, 396, 399
 India 396, 399
 Pakistan 399
 Philippines 399
 Vietnam 399
ASO3 191
Assembly 37, 47
Asthma 411
- B**
- B16F10 265
Bacillus Calmette–Guerin *see* BCG
Bacteraemia 388, 389, 393, 398
BAM format 41
Basophil 223
B-cells 220, 222, 223, 226, 336, 393–395, 398, 401
B-cell germinal centres 337
B-cell memory 133
B-cell receptor (BCR) 17, 335
BCG 251, 256, 258, 306–312
BEAST analysis 70
 β -chemokines 337
Bexsero 4
Bill and Melinda Gates Foundation 397

- BLAST 36
 Blood culture 388, 389
 Blood stage challenge 285
 Blood stage vaccines 293
 BnAbs 344–350
 Boosting 397
Bordetella pertussis 227, 228, 236, 237
 Bovine RSV 414
 Bovine serum albumin 414
 Broadly neutralizing antibodies 335
 Bronchiolitis 411–412
 BRSV 414–415
 BW transform 36
- C**
- CS57/B6 265
 C type lectin receptors CLR 188–189
 Cancer immunotherapy 359–377
 Cancer Immunotherapy Consortium (CIMT) 267
 Cancer mutations 263–264
 discovery 263
 non-synonymous 266
 selection 266
 Cancer vaccines 360–370
 antigenic 362–363, 366–367
 see also peptide *under* Cancer vaccines
 anti-idiotype 362–363, 369
 dendritic cell 361–365
 DNA 362–363, 367–368
 exosomes 365
 heat shock proteins 366
 peptide 362–363, 366–367
 tumor cell 360–363
 viral 362–363, 368–369
Candida albicans 229
 Carrier proteins 398, 399, 400
 CRM₁₉₇ 398, 399
 Pseudomonas aeruginosa recombinant exoprotein A (rEPA) 399
 tetanus toxoid 398, 399
 Case fatality 388, 396
 CD107a 340
 CD14 402
 CD4 T-cell 222, 224, 226, 236, 311, 313–314, 325, 335–339, 348
 T_{CM} 311, 325
 T_{EM} 311, 325
 Th1 313
 Th17 313–314
 CD8 T-cell 222–224, 226, 230, 231, 238, 314
 CD8 T cytolytic 337, 338
 cDNA 13
 Cellular immunity 219, 220, 235, 420
 Cellular phenotype and function 144
 Cellular screens 139
 Clonal expansion 134
 CH63 342
 Challenge (with *Salmonella*) 392, 399–401
 Challenges for next decade 208
 Chemokines 160, 161, 163, 165
 Children 395, 396, 399
 ChIP-seq 15, 35, 51–52
 CHMI 284, 286, 287
 Choice of endpoints 288
 Chronic carriage 389, 393
 Circumsporozoite protein 281
 see also CS
 Circumsporozoite protein 290
Citrobacter 399
 Class II HLA 337
 Clinical management 388
 Clinical presentation 387, 388
 Clinical trials 395, 399, 400
Clostridium difficile 65, 66, 70
 Clumping factor A (ClfA) 428–429
 Clustering 53
 CMV vaccine 341
 Coalition against Typhoid (CaT) 397, 403
 Cold chain 396
 Colonization 437–438
 Comparative genomics 12, 65–74
 Complement 392, 393
 Controlled human malaria infection 284
 see also CHMI
 Correlate of protection 415
 Cost of goods 397
 Cotton rats 413–414, 418
 CP5-CRM197 428–429
 CP5-Epa 426–427
 CP8-CRM197 428–429
 CP8-EPA 426–427
 CpG ODN 198
 Cre-Lox recombination 18
 Cross-protection 395, 396
 Cross-reactivity 401
 Cryo-EM 111–113, 117
 Cryopreserved sporozoites 285
 CS 281, 286
 Csa1A 430
 CSP 290
 see also CS
 CXCR5 338
 Cytokines 392
 IFN γ 391, 393, 398
 IL-12 393
 IL-18 393
 TNF α 393
 Cytotoxic lymphocyte 229
- D**
- De Bruijn graph 38
 Deep sequencing 7
 Dendritic cells 157, 220, 223, 226, 230, 235
 see also Dermal dendritic cells
 Dermal dendritic cells (dDC) 157–176
 Dermis 158, 159, 161, 162, 165–167, 169–172
 Diabetes 305
 Diagnosis 388
 Diarrheagenic *E. coli* 67, 68, 70
 Dideoxy chain termination method 6
 DNA 3, 337, 349
 DNA methylation 14

- DNA sequencing 3
 DNA vaccine 251, 254, 257, 258
 Driver mutation 264
 Drug-resistant TB 306, 326
 MDR-TB 306
 XDR-TB 306
- E**
- EAEC 71, 72, 73
 EBA-175 293
 EBV transformation 141
 ECGC 263
 Effectiveness 394, 398, 400, 403
 Effector functions 137
 Efficacy 387, 392, 395–397, 399
 Efficacy endpoint 285
 EHEC 71, 72
 Electron microscopy 103–104, 111–112
 ELISPOT assay 140, 252
 EM 54
 Emulsions 191
 Enhanced respiratory disease 412
 Enteric fever 387–390, 393, 396–399, 402
 Environmental mycobacteria 308–310
 Eosinophil 223
 EPI 287
 Epidemiological 387, 391, 392, 398, 403
 Epidemiology 70
 Epidermal immunization 169, 175
 Epidermis 157–176
 Epigenomics 10, 14
 Epitope mapping 103–111, 113–126
 Epitopes 44–46, 419
 ERD 412–416, 418, 420
 Erythrocyte-binding antigen-175 293
 Erythrocytic-stage antibody mediated immunity 282
 Erythrocytic-stage T-cell immunity 283
Escherichia coli 65–68, 221, 233
 ETEC 66, 71, 72
 Expanded Programme on Immunizations (EPI) 397–399
 Expectation Maximization *see* EM
 Extracellular 388, 391, 393
- F**
- FhuD2 429–430
 Field evaluation of malaria vaccine 288
 First-generation sequencing (FGS) 8
 FI-RSV 412–413, 418
 FM index 36
 Formalin-inactivated 412
 Food and Drug Administration (FDA) 267
 Fragment-display 106–107, 110, 117
 Fusion protein 411, 418
- G**
- Gall bladder 388, 390
 GAPs 292
 Gastroenteritis 387, 391
 GAVI Alliance 397
 GBS 116–119
- Global burden 388
 Global health 387, 402
 Gene prediction 39
 Genes 390, 391, 400–403
 aroC 400
 aroD 400
 clpP 400
 gna33 401
 guaBA 400
 htrA 400
 htrB 402
 msbB 402
 PhoP/PhoQ 400
 ssaV 400
 tolR 401
 Genetic diversity 388
 Genetically attenuated parasites 292
 see also GAPs
 Genome 387, 398, 400, 401, 403
 Genome-wide association studies (GWAS) 12
 Genomic viewer 40–41
 Genomics 10, 12, 133
 Gd T-cell 222, 223, 231–233, 238, 239
 GLURP 279, 293
 Glutamate-rich protein 293
 gp120 349
 gp120 CD4 binding site 345
 Granuloma 312
- H**
- Haemophilus influenzae* B 398
 Hair follicle 160, 169–172, 176
 Haitian cholera outbreak 69
 HapMap 34
 Hash table 36
 HCV 35
 H/DX-MS 108–109, 117
Helicobacter 229
 Heterogeneity in malaria exposure 289
 Hidden Markov model *see* HMM
 High-income countries 387, 397, 399
 High-throughput sequencing 142
 HIV 149, 305–306, 389, 390, 392, 398, 400
 HIV-1 335–352
 HIV vaccine 334, 349
 HLA 34, 278
 HMM 39
 HMP 34
 Human adenovirus 291
 see also AdH5
 Human Genome Project (HGP) 6
 Humanized mice 283
 Humoral immunity 219, 220, 227
 Hybridoma technology 141
 Hyporesponsiveness 396
- I**
- ICOS 337
 ICTV 41
 IEDB Immune Epitope database 267
 Ig 42

- Ig-seq 17
 IMG 41
 Imiquimod 194
 Immune checkpoint blockade 370–374
 CTLA-4 370–372
 PD-1 371–374
 Immune recognition 265
 Immune system 219, 220
 Immunity 387, 388, 390–403
 acquired immunity 387, 391
 cellular immunity 391–393, 396, 398–400
 humoral immunity 391–393
 herd immunity 397, 398
 innate immunity 391, 394, 402
 mucosal immunity 400, 402
 pan-specific immunity 395
 systemic immunity 400
 Immunity to erythrocytic stages 278
 Immunity to sexual stages 279
 Immunodeficiency 391
 chronic granulomatous disease 391
 common variable immunodeficiency (CVID) 391
 Immunogenicity 395, 399, 400, 402
 Immunogenicity testing 265
 Immunoglobulin *see* Ig
 Immunological memory 133
 Immunome 16
 Immunomodulatory 394
 Immunotherapy, cancer 359–377
 Incidence 389, 390, 392, 398
 Infants 395, 396, 398
 Infection under treatment vaccination 292
 see also ITV
 Influenza virus 147
 Innate immunity 187, 219, 220
 Innate like-lymphocyte 222, 231, 238
 Innovation 387, 394, 399, 401, 403
 Interferon- γ 222, 225, 226, 231–233
 Interleukin-10 (IL-10) 229
 Interleukin-17 (IL-17) 222, 227, 232, 234, 239
 Interleukin-22 (IL-22) 222, 229, 239
 International Conference on Harmonization (ICH) 267
 Intracellular 388, 390, 391, 393, 394, 398, 403
 Intradermal 166–167, 169, 172, 174–176
 iNTS disease 387–394, 396–402
 Invasive non-typhoidal *Salmonella* 70
 In vitro transcribed (IVT) RNA 267
 Irradiated sporozoites 280
 IsdB 427, 428
 ITV 292
- K**
- Killer inhibitory receptor (KIR) 344
Klebsiella pneumoniae 65, 66, 69, 227, 229
 KPC 69
 Kynureninase (KYNU) 346
- L**
- Langerhans cells (LC) 157–175
 Lessons learned from TLR agonists 203
 Licensed 387, 394–396
 Limited values of animal work 208
 Lipopeptides 251
 Lipopolysaccharide (LPS) 388, 392, 394, 399, 401, 402
 Live attenuated 412, 416
 Long lived plasma cell 136
 Low-income countries 387, 388, 397, 399
 Lujo virus 34
 Lymphoid tissue inducer cells (iT_L) 222
- M**
- Macrophage 223, 225, 226, 239
 Major histocompatibility complex 223, 224, 226, 230, 231
 Malaria 273, 389, 391
 Malaria control approaches 274
 Malaria life cycle 276
 Malaria parasites 274
 Malaria vaccine development 289
 Manufacturers 397, 403
 Mapping 35–36
 Markov model 39
 Mass spectrometry 103, 107–109
 Massive parallel sequencing 7
 Maternal immunization 415–417
 Maximum likelihood 41
 Mechanism 391, 392, 394
 Membrane proximal external region (MPER) 345
 Memory 395, 396, 398
 MenB 119–121
 Meningitis 388
 Meningococcus 398, 399, 401
 Merozoite surface protein 1 293
 see also MSP-1
 Merozoite surface protein 2 293
 see also MSP-2
 Merozoite surface protein 3 293
 see also MSP-3
 Merozoites 276–278
 Meta-analysis 395
 Metagenomic analysis 19
 Metagenomics 10, 52
 MetaHIT 34
 Methicillin-resistant *Staphylococcus aureus* (MRSA) 237
 ME-TRAP 277, 291
 MF59 191
 MHC 44–45
 MHC tetramers 146
 Microbiome 12
 Middle-income countries 396
 MIP-1 β 340
 miRNA 13, 48–49
 MLEE 65
 MLST 65
 MLVA 65
 MntC 429
 Modified Vaccinia virus Ankara *see* MVA
 Molecular 72
 Monoclonal antibodies 140
 Monocyte 223
 Mouse 391, 392, 394, 399–401
 MRSA 65, 66, 69

- MSP-1 293, 279, 283
MSP-2 293
MSP-3 279, 293
Mucosa 392
Multiparametric flow cytometry 146
Multiple TLR activation 205
Murine model 280, 283
Mutagenesis 396, 400, 402
Mutanome 263
Mutanome vaccines 264
Mutation 391, 400, 401, 403
MVA 251, 255, 257, 258, 291, 337, 342
Mycobacterium tuberculosis 231, 234
- N**
- NANP 290
National Institutes of Health (NIH), US 399
Native outer membrane vesicles (NOMV) 401
Natural killer T-cells (NKT-cells) 222, 223, 234, 235, 238, 239
NDV-3 426
 see also rAls3p-N
Needle-free 169
Neisseria meningitidis 4
Neo-antigen 264
Neutrophil 223, 225, 227, 239
Next-generation sequencing *see* NGS
NGS 7, 41, 263
 clinical grade 266
 exome analyses 266
 non-synonymous 266
NK cells 391
NMR 103–104, 110–112, 117, 120
NOD like receptors NLR 188–189
Non TLR adjuvants 191
Non-coding regulatory elements (ncRNAs) 13
Non-human primate malaria models 283
NYVAC 349
- O**
- O104:H4 65, 66, 71
O157:H7 65, 66, 71, 72
O55:H7 72
Opsonization 220, 392
OUT 53
Outbreak 66, 67
Out-bred mice 283
Outer membrane vesicles (OMV) 5
Overlap extension PCR 18
Overlap-layout consensus 37
Oxidative burst 391, 393
- P**
- P52 292
Pagibaximab 431, 438
Palivizumab 412, 420
Panton–Valentine leukocidin 434–436
Paratyphoid 399
Passive transfer 391, 392
Pathogen-associated molecular patterns (PAMPs) 188, 220
Pathogen recognition receptors (PRR) 220, 229
Pattern recognition receptors (PRR) 188
PCR 285
PD1 338
Peptide stimulation 145
Personalized cancer immunotherapy 263
Personalized medicine 263
Personalized vaccines 267
PfEMP-1 278
PFGE 69
Pfs230 294
Pfs25 294
Pfs28 294
Pfs45/48 294
Phagocytes 388, 391, 392
 macrophages 388, 390, 391, 393, 394, 400
 neutrophils 391, 393
Phylogeny 41, 66
piRNAs 13
Plasma cell 133
Plasmablasts 18, 136
Plasmacytoid dendritic cells (PDC) 343
Plasmodium falciparum 274
Plasmodium knowlesi 274
Plasmodium malariae 274
Plasmodium ovale 274
Plasmodium vivax 274
Pneumococcus 398, 399
Pneumovirus 411
Poisson model 50
Polymorphism 391
Poly-N-acetylglucosamine (PNAG) 434, 436–437
Polysaccharide 387, 388, 390, 392, 393, 396–399
Population 387–389, 397
Post-fusion 419
Post-licensure surveillance 19
Pre-erythrocytic immunity 277
Pre-erythrocytic malaria vaccine 289
Pre-erythrocytic vaccines 277, 286
Pre-fusion 418–419
Primary malaria endpoints 287
Primer-/ bead barcoding 18
Prophage 54
Protection 390–392, 394, 396, 398, 400, 401, 403
Protective immunity 133
Protein A 435–436
Proteins 388, 392–402
 outer membrane proteins 392, 394, 400–402
 porins 394, 401, 402
 purified proteins 395, 397, 400, 402
 recombinant proteins 395, 397, 400, 401
Pseudomonas aeruginosa 221
Public health 387
- Q**
- Quasispecies 54
- R**
- Radiation attenuated sporozoites 292
 see also RAS
RAS 292

- rAls3p-N 426
 - see also* NDV-3
 - RD1 316
 - Reactogenicity 395, 402
 - Receptor repertoire 133
 - REP-PCR 65
 - Resiquimod 196
 - Respiratory syncytial virus 411
 - Reverse vaccinology 4, 401
 - Ribo-seq 14
 - RIG-I like receptors RLR 188–189
 - RNA 13, 417
 - RNA-seq 13, 35, 46
 - RPKM 51
 - rRNAs 13
 - RSV 411–421
 - RSV F 412–420
 - RSV G 420
 - RTS,S 277, 290
 - RTS,S development 290
 - AS01 291
 - AS02 290
 - AS04 290
 - RV144 335–336, 348
- S**
- Safety 399, 400
 - Safety considerations of TLR agonists 208
 - Salmonella* vaccines 387–403
 - Generalized modules for membrane antigens (GMMA) 393, 395, 397, 401–403
 - glycoconjugate 392, 394–403
 - inactivated whole cell 394, 395, 397, 400
 - live-attenuated 387, 393–397, 400, 403
 - subunit 396, 398–401
 - Ty21a 387, 390, 395–397, 400
 - Vi capsular polysaccharide vaccine (Vi CPS) 387, 390, 395–398, 400
 - SAM vaccine 417
 - SAP1 292
 - Scaffolded antigen 420
 - Second-generation systems (SGS) 7
 - SERA-5 293
 - Serine repeat antigen 5 293
 - see also* SERA-5
 - Serovars (of *Salmonella enterica*) 387, 388, 392–394, 396, 398–401
 - Dublin 388
 - Enteritidis 397, 389, 390, 393, 398, 399, 400
 - Paratyphi A 387–389, 393, 394, 396, 398, 399
 - Paratyphi B 395, 396
 - Paratyphi C 388
 - Typhi 387–390, 392–401
 - Typhimurium 387, 389, 390, 392–394, 398–401
 - Shigella* 67, 68
 - Shigella sonnei* 68
 - Simian immunodeficiency virus (SIV) 392
 - Single cell expression cloning 140
 - Single nucleotide polymorphisms (SNPs) 12, 65, 66, 69, 70
 - Single nucleotide variations (SNV) 37, 264
 - siRNAs 13
 - Skin 157–176
 - Skin resident T cells (TRM) 165, 169
 - SLC11A 391
 - snoRNAs 13
 - SNP phylogeny 66, 67
 - SNP typing 68
 - snRNAs 13
 - Somatic hypermutation (SHIM) 42–43, 337
 - Somatic mutation 42
 - spa* typing 69
 - SPf66 289
 - Splice junction 47
 - Sporozoites 276
 - ST239 69
 - Staphylococcus aureus* 18, 221, 222, 228, 237, 238, 425–440
 - StaphVAX 426–427
 - Statistical confidence 265
 - STEBVax 426, 428
 - Streptococcus pneumoniae* 232, 234–236
 - Structural 418–419
 - Structural genomics 15
 - Structural vaccinology 103–106, 116, 118–119, 123, 125, 128
 - Structure-based detoxification 121–123
 - Subunit vaccine approach 293
 - Suffix tree 36
 - Synthetic biology 18
 - Synthetic libraries 105–106, 117
 - Synthetic seed 19
 - Synthetic virus 19
 - Systems biology 16
 - Systems vaccinology 17
- T**
- T helper 1 cell (Th1) 225, 226, 228, 236–238
 - T helper 17 cell (Th17) 225, 227, 228, 236–238
 - T helper 2 cell (Th2) 225–227
 - T helper 22 cell (Th22) 225, 229
 - T regulatory cell (Treg) 225, 229, 230, 337
 - TBV 293
 - T-cell memory 133
 - T-cell receptor *see* TCR
 - T-cells 220, 221, 222, 224, 238, 223, 232, 336, 388, 391–396, 398–402
 - CD4⁺ T-cells 392–394
 - CD4⁺ T-cells 393
 - γδT cells 391
 - NKT cells 391
 - Th17 cells 393
 - TCGA (The Cancer Genome Atlas) 263
 - TCR 17, 42
 - T-dependent 395, 398, 399
 - Tefibazumab 431, 439
 - Teleporting life 18
 - T-follicular helper (Tfh) 337
 - Th1 337
 - Th17 337
 - Th2 337, 413
 - Third-generation systems (TGS) 7

- Third heavy chain complementarity-determining region (HCDR3s) 345
- Third variable (V3) loop 345
- Thrombospondin-related adhesion protein 281
see also TRAP
- T-independent 396, 398
- TLR agonists against cancer 202
- TLR agonists against tuberculosis 202
- TLR agonists direct and indirect 205
- TLR agonists in HIV 199
- TLR agonists in malaria 201
- TLR based adjuvants 192
- TLR cross talk 206
- TLR2 192
- TLR3-4 193
- TLR4 402
- TLR5 394, 402
- TLR5,7 194
- TLR7/8 196
- TLR8 197
- TLR9 198
- TLRs in non-immune cells 206
- TMM 51
- Tn21-like element 70
- Tn6192 70
- Tolerability 399, 400
- Toll-like receptor (TLR) 162, 163, 173, 175, 189–206
- Toll-like receptor agonists 420
- Tol-Pal system 401, 402
- Transcriptome 46
- Transcriptomics 10, 13
- Transgenic parasites 283
- Transmission 387, 388, 391, 397, 398, 400
- Transmission blocking vaccines 293
see also TBV
- Transmitted/founder (T/F) viron 336
- TRAP 281, 282, 286
- Treatment 412
- tRNAs 13
- Tumour immunotherapy 359–377
- Typhoid 388–390, 392, 394, 396, 398, 399, 401
- Ty VLPs 251, 254, 257
- U**
- UIS3 292
- UIS4 292
- Up-regulated infectious sporozoite gene-3 292
see also UIS3
- Up-regulated infectious sporozoite gene-4 292
see also UIS4
- V**
- Vaccination *see* Vaccines
- Vaccine companies 396
- Bharat Biotech 396, 399
- BioMed 396, 399
- Emergent Biosolutions 400
- Lanzhou Institute 396, 399
- Shantha Biotech 396
- Vaccine coverage 393, 395, 398–400
- Vaccine design 390, 394, 396, 397, 399
- Vaccine institutes 396, 403
- Center for Vaccine Development (CVD) 396, 400
- International Vaccines Institute (IVI) 396, 399
- Novartis Vaccines Institute for Global Health (NVGH) 396, 399, 401
- Sabin Vaccine Institute 397
- Vaccines 133, 220, 221, 235, 237, 238, 412–421
 anti-tumor *see* Cancer vaccines
- Vaccinomics 17
- Variants calling 37
- VDJ recombination 42, 134
- Vectored 417
- Veronate 430–431, 439
- Vibrio cholerae* 66, 69
- Viral pathogen 105–106, 116, 123, 125
- Viral vectors 317, 321, 322–323
- adenovirus 321, 323
- fowl pox (FP) 317–318
- modified vaccinia ankara (MVA) 317
- Virulence 388, 391
- Virus-like particle (VLP) 173, 172, 175, 192
- VLPs with peptides 251, 254
- W**
- WHO 392, 396, 397
- Whole genome alignment 68–71
- Whole-genome sequencing (WGS) 12
- Whole-shotgun sequencing 6
- X**
- X-ray crystallography 103–104, 109–111, 117, 126